Myocardial ischemia
Therapeutic area
Cardiology
Rare disease
No
- Definition
- A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (coronary artery disease), to obstruction by a thrombus (coronary thrombosis), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Myocardial ischemia
- Therapeutic area
- Cardiology
- myocardial ischemia
- Heart Diseases, Ischemic
- IHD
- ischaemic disease of myocardium
- ischaemic heart disease
- Ischaemic Heart Disease (IHD)
- Ischaemic Heart Diseases
- Ischemia, Myocardial
- ischemic disease of myocardium
- ischemic heart disease
- Ischemic Heart Disease (IHD)
- Ischemic Heart Diseases
- Myocardial Ischemia, Angina Pectoris
- myocardium ischaemic disease
- myocardium ischemic disease
- disease, ischaemic heart
- disease, ischemic heart
- diseases, ischaemic heart
- diseases, ischemic heart
- heart disease, ischaemic
- heart disease, ischemic
- heart diseases, ischaemic
- ischemias, myocardial
- myocardial Ischemias
- Severity
- Severe
- Cardiology
- Vascular Medicine
Sources for recorded values
- MONDO ID
- MONDO:0024644
- Parent condition
- MONDO:0005053
Related records
Broader conditions (8)
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Heart disorder
- Human disease
- Ischemic disease
- Myocardial disorder
- Vascular disorder
Narrower conditions (1)
Trials (2,587)
- 'MInimalist' or 'MOre Complete' Strategies for Revascularization in Octogenarians
- "L-Sandwich" Strategy in the True Coronary Bifurcation Lesions
- "Nutrition Education by Nurses in Patients After Coronary Artery Bypass Grafting: Effect on Patients' Dietary Pattern, Adherence and Clinical Outcomes"
- "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
- 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- 123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients
- 18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability
- 18F-FMPP PET MPI in the Detection of Coronary Artery Disease
- 20 Year Changes in Fitness & Cardiovascular Disease Risk - Ancillary to CARDIA
- 3 Limus Agent Eluting Stents With Different Polymer Coating
- 320 Multidetector Computed Tomography Prior to Coronary Artery Bypass Surgery
- 4-electrode ECG (DigitalCardio®) vs Standard 10-electrode ECG: Evaluating Ease of Use and Recording Quality
- 68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease
- 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
- A Biorepository for Coronary Heart Disease in Qatar
- A CCTA Image Assisted Triage Software for the Assessment of Patients With Suspected Coronary Artery Disease
- A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
- A Clinical Evaluation of AMJ-401
- A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions
- A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System
Approved drugs (2)
- Clopidogrel bisulfate
- Prasugrel hydrochloride
Drugs in development (88)
- Abciximab Phase 3
- Adenosine Phase 3
- Alcohol Phase 2
- Aldesleukin Phase 1
- Alteplase Phase 3
- Amlodipine Phase 3
- Arginine Phase 1
- Ascorbic acid Phase 3
- Aspirin Phase 3
- Atenolol Phase 3
- Beta carotene Phase 2
- Calcium Phase 3
- Chlorthalidone Phase 3
- Cholestyramine Phase 3
- Clofibrate Phase 3
- Clopidogrel Phase 3
- Colestipol hydrochloride Phase 3
- Cyanocobalamin Phase 2
- Dapagliflozin Phase 1
- Dextrothyroxine sodium Phase 3
Other linked drugs (22)
- Bradykinin
- Clopidogrel besilate
- Clopidogrel hydrobromide
- Clopidogrel hydrochloride
- Empagliflozin
- Ertugliflozin
- Ertugliflozin pidolate
- Ethinyl estradiol
- Linagliptin
- Metformin
- Metoprolol
- Milrinone
- Norethindrone
- Prasugrel
- Prasugrel besylate
- Sevoflurane
- Sirolimus
- Sitagliptin
- Ticagrelor
- Umirolimus